Phase 2 Dose-Finding Study in Patients with Gout Using SEL-212, a Novel PEGylated Uricase (SEL-037) Combined with Tolerogenic Nanoparticles (SEL-110)

Autor:	Alan Kivitz, Wesley DeHaan, Rehan Azeem, Justin Park, Sheri Rhodes, Jamie Inshaw, Sheldon S. Leung, Savvas Nicolaou, Lloyd Johnston, Takashi K. Kishimoto, Peter G. Traber, Earl Sands, Hyon Choi
Jazyk:	angličtina
Rok vydání:	2023
Předmět:	Gout Hyperuricemia ImmTOR® Polyethylene glycols SEL-212 Uric acid Diseases of the musculoskeletal system RC925-935
Zdroj:	Rheumatology and Therapy, Vol 10, Iss 4, Pp 825-847 (2023)
Druh dokumentu:	article
ISSN:	2198-6576 2198-6584
DOI:	10.1007/s40744-023-00546-0
Popis:	Abstract Introduction SEL-212 is a developmental treatment for uncontrolled gout characterized by serum uric acid (sUA) levels ≥ 6 mg/dl despite treatment. It comprises a novel PEGylated uricase (SEL-037; also called pegadricase) co-administered with tolerogenic nanoparticles containing sirolimus (rapamycin) (SEL-110; also called ImmTOR®), which mitigates the formation of anti-drug antibodies (ADAs) against uricase and SEL-037 (PEGylated uricase), thereby enabling sustained sUA control (sUA
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/cf6f1cb3ba274f37b044035ffe0ee7d4 Zobrazit plný text záznamu View record in DOAJ Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.